<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862469</url>
  </required_header>
  <id_info>
    <org_study_id>2018-1533</org_study_id>
    <nct_id>NCT03862469</nct_id>
  </id_info>
  <brief_title>Premenstrual Hormonal and Affective State Evaluation (PHASE) Project</brief_title>
  <acronym>PHASE Project</acronym>
  <official_title>Premenstrual Hormonal and Affective State Evaluation (PHASE) Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PHASE is designed to evaluate the HPA axis, heart rate, heart rate variability and affect in
      women with Premenstrual Syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy volunteers will be recruited from the community for participation in this 3-menstrual
      cycle study. In the first two menstrual cycles, study participants will chart their symptoms
      and use Easy@Home Ovulation strip to chart their ovulation using the PreMom app. This period
      will separate study participants into two groups: those with vs. without the PMS diagnosis.
      Study participants will continue to perform ovulation testing during their third menstrual
      cycle. They will attend one individualized task session and provide 8 serum samples at
      specific ovulation-guided menstrual cycle times.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hormone Analysis</measure>
    <time_frame>2 hours</time_frame>
    <description>Allopregnanolone, cortisol, progesterone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular function</measure>
    <time_frame>2 hours</time_frame>
    <description>Heart Rate, Heart Rate Variability</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Affect</measure>
    <time_frame>2 hours</time_frame>
    <description>Subjective Mood States</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Premenstrual Syndrome</condition>
  <arm_group>
    <arm_group_label>Study Procedure (all participants)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Diagnostic Phase (2 months): at-home urine hormone testing and completion of daily online surveys.
Individualized Task (-6 to -2 days from the subsequent menstrual cycle)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Individualized laboratory test</intervention_name>
    <description>Laboratory test administered between 6 and 2 days prior to the subsequent menstrual cycle.</description>
    <arm_group_label>Study Procedure (all participants)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  Aged 18-35 years, established by visual inspection of a government-issued ID

          -  Average menstrual cycle 21-35 days

          -  Access to smartphone with working camera for daily use of the PreMom application

        Exclusion Criteria:

          -  Lifetime DSM-5 Axis 1 disorder (except anxiety and depression), as documented in the
             Mental Health Interview

          -  Current DSM-5 Axis depressive or anxiety disorder, as documented in the Mental Health
             Interview

          -  Positive urine drug screen test

          -  Breath alcohol concentration &gt;0.00%

          -  Self-reported smoker or carbon monoxide concentration ≥ 6 ppm

          -  Irregular menstrual cycle

          -  Current pregnancy (urine test-verified) or lactation, or a plan to become pregnant

          -  Moderate or high suicide risk

          -  Shipley IQ (vocabulary standard score) &gt; 80

          -  Prescription medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ajna Hamidovic, PharmD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ajna Hamidovic, PharmD, MS</last_name>
    <phone>312-355-1713</phone>
    <email>ahamidov@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yohyoh Wang</last_name>
    <phone>312-996-8838</phone>
    <email>yohyoh@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Illinois Department of Pharmacy Practice</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ajna Hamidovic, PharmD</last_name>
      <phone>312-355-1713</phone>
      <email>ahamidov@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yohyoh Wang</last_name>
      <phone>(312) 996-8838</phone>
      <email>yohyoh@uic.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Allen AP, Kennedy PJ, Dockray S, Cryan JF, Dinan TG, Clarke G. The Trier Social Stress Test: Principles and practice. Neurobiol Stress. 2016 Nov 12;6:113-126. doi: 10.1016/j.ynstr.2016.11.001. eCollection 2017 Feb. Review.</citation>
    <PMID>28229114</PMID>
  </reference>
  <reference>
    <citation>American College of Obstetricians and Gynecologists. Premenstrual Syndrome. ACOG Practice Bulletin No. 15. Washington, DC: American College of Obstetricians and Gynecologists, 2000.</citation>
  </reference>
  <reference>
    <citation>Bäckström T, Sanders D, Leask R, Davidson D, Warner P, Bancroft J. Mood, sexuality, hormones, and the menstrual cycle. II. Hormone levels and their relationship to the premenstrual syndrome. Psychosom Med. 1983 Dec;45(6):503-7.</citation>
    <PMID>6686333</PMID>
  </reference>
  <reference>
    <citation>Carlin, J. B., Galati, J. C., &amp; Royston, P. (2008). A new framework for managing and analyzing multiply imputed data in Stata. Stata Journal, 8(1), 49-67.</citation>
  </reference>
  <reference>
    <citation>Critchlow DG, Bond AJ, Wingrove J. Mood disorder history and personality assessment in premenstrual dysphoric disorder. J Clin Psychiatry. 2001 Sep;62(9):688-93.</citation>
    <PMID>11681764</PMID>
  </reference>
  <reference>
    <citation>Cunningham J, Yonkers KA, O'Brien S, Eriksson E. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17(2):120-37. doi: 10.1080/10673220902891836. Review.</citation>
    <PMID>19373620</PMID>
  </reference>
  <reference>
    <citation>Deng D, Pang Y, Duan G, Liu H, Liao H, Liu P, Liu Y, Li S, Chen W, Wen D, Xuan C, Li M. Larger volume and different functional connectivity of the amygdala in women with premenstrual syndrome. Eur Radiol. 2018 May;28(5):1900-1908. doi: 10.1007/s00330-017-5206-0. Epub 2017 Dec 19.</citation>
    <PMID>29260367</PMID>
  </reference>
  <reference>
    <citation>Endicott J, Nee J, Harrison W. Daily Record of Severity of Problems (DRSP): reliability and validity. Arch Womens Ment Health. 2006 Jan;9(1):41-9. Epub 2005 Sep 20.</citation>
    <PMID>16172836</PMID>
  </reference>
  <reference>
    <citation>Fischer S., Clear A. J. (2017). Cortisol as a predictor of psychological therapy response in anxiety disorders-Systematic review and meta-analysis. Harv Rev Psychiatry, 17(2), 120-37. doi:10.1080/10673220902891836</citation>
  </reference>
  <reference>
    <citation>Hamidovic A, Childs E, Conrad M, King A, de Wit H. Stress-induced changes in mood and cortisol release predict mood effects of amphetamine. Drug Alcohol Depend. 2010 Jun 1;109(1-3):175-80. doi: 10.1016/j.drugalcdep.2009.12.029. Epub 2010 Feb 21.</citation>
    <PMID>20176450</PMID>
  </reference>
  <reference>
    <citation>Howards PP, Schisterman EF, Wactawski-Wende J, Reschke JE, Frazer AA, Hovey KM. Timing clinic visits to phases of the menstrual cycle by using a fertility monitor: the BioCycle Study. Am J Epidemiol. 2009 Jan 1;169(1):105-12. doi: 10.1093/aje/kwn287. Epub 2008 Oct 30.</citation>
    <PMID>18974081</PMID>
  </reference>
  <reference>
    <citation>Kirschbaum C, Pirke KM, Hellhammer DH. The 'Trier Social Stress Test'--a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology. 1993;28(1-2):76-81.</citation>
    <PMID>8255414</PMID>
  </reference>
  <reference>
    <citation>Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry. 2006 May;63(5):484-9.</citation>
    <PMID>16651505</PMID>
  </reference>
  <reference>
    <citation>Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research. J Psychiatr Res. 2011 May;45(5):626-9. doi: 10.1016/j.jpsychires.2010.10.008. Epub 2010 Oct 28.</citation>
    <PMID>21035130</PMID>
  </reference>
  <reference>
    <citation>Lovick TA. Estrous cycle and stress: influence of progesterone on the female brain. Braz J Med Biol Res. 2012 Apr;45(4):314-20. Epub 2012 Mar 29.</citation>
    <PMID>22450372</PMID>
  </reference>
  <reference>
    <citation>Moore CG, Carter RE, Nietert PJ, Stewart PW. Recommendations for planning pilot studies in clinical and translational research. Clin Transl Sci. 2011 Oct;4(5):332-7. doi: 10.1111/j.1752-8062.2011.00347.x. Review.</citation>
    <PMID>22029804</PMID>
  </reference>
  <reference>
    <citation>Qiao M, Zhang H, Liu H, Luo S, Wang T, Zhang J, Ji L. Prevalence of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample in China. Eur J Obstet Gynecol Reprod Biol. 2012 May;162(1):83-6. doi: 10.1016/j.ejogrb.2012.01.017. Epub 2012 Feb 28.</citation>
    <PMID>22377229</PMID>
  </reference>
  <reference>
    <citation>Rubinow DR, Schmidt PJ. Gonadal steroid regulation of mood: the lessons of premenstrual syndrome. Front Neuroendocrinol. 2006 Jul;27(2):210-6. Epub 2006 May 2. Review.</citation>
    <PMID>16650465</PMID>
  </reference>
  <reference>
    <citation>Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med. 1998 Jan 22;338(4):209-16.</citation>
    <PMID>9435325</PMID>
  </reference>
  <reference>
    <citation>Sohda S, Suzuki K, Igari I. Relationship Between the Menstrual Cycle and Timing of Ovulation Revealed by New Protocols: Analysis of Data from a Self-Tracking Health App. J Med Internet Res. 2017 Nov 27;19(11):e391. doi: 10.2196/jmir.7468.</citation>
    <PMID>29180346</PMID>
  </reference>
  <reference>
    <citation>Solís-Ortiz S, Corsi-Cabrera M. Sustained attention is favored by progesterone during early luteal phase and visuo-spatial memory by estrogens during ovulatory phase in young women. Psychoneuroendocrinology. 2008 Aug;33(7):989-98. doi: 10.1016/j.psyneuen.2008.04.003. Epub 2008 Jul 21.</citation>
    <PMID>18644678</PMID>
  </reference>
  <reference>
    <citation>Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane M, Giangregorio L, Goldsmith CH. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010 Jan 6;10:1. doi: 10.1186/1471-2288-10-1.</citation>
    <PMID>20053272</PMID>
  </reference>
  <reference>
    <citation>Toffol E, Heikinheimo O, Partonen T. Associations between psychological well-being, mental health, and hormone therapy in perimenopausal and postmenopausal women: results of two population-based studies. Menopause. 2013 Jun;20(6):667-76. doi: 10.1097/gme.0b013e318278eec1.</citation>
    <PMID>23277355</PMID>
  </reference>
  <reference>
    <citation>Whooley MA, Grady D, Cauley JA. Postmenopausal estrogen therapy and depressive symptoms in older women. J Gen Intern Med. 2000 Aug;15(8):535-41.</citation>
    <PMID>10940144</PMID>
  </reference>
  <reference>
    <citation>Yen JY, Wang PW, Su CH, Liu TL, Long CY, Ko CH. Estrogen levels, emotion regulation, and emotional symptoms of women with premenstrual dysphoric disorder: The moderating effect of estrogen receptor 1α polymorphism. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:216-223. doi: 10.1016/j.pnpbp.2017.11.013. Epub 2017 Nov 14.</citation>
    <PMID>29146473</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Ajna Hamidovic, PharmD, MS</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premenstrual Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

